DOCS vs. TEM, RMG, VTY, SPT, GEN, WIX, YOU, CNIC, SRAD, and SLP
Should you be buying Dr. Martens stock or one of its competitors? The main competitors of Dr. Martens include Templeton Emerging Markets Investment Trust (TEM), Royal Mail (RMG), Vistry Group (VTY), Spirent Communications (SPT), Genuit Group (GEN), Wickes Group (WIX), YouGov (YOU), CentralNic Group (CNIC), Stelrad Group (SRAD), and Sylvania Platinum (SLP). These companies are all part of the "computer software" industry.
Dr. Martens vs. Its Competitors
Dr. Martens (LON:DOCS) and Templeton Emerging Markets Investment Trust (LON:TEM) are both computer software companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
Dr. Martens presently has a consensus price target of GBX 6,000, suggesting a potential upside of 7,480.54%. Given Dr. Martens' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Martens is more favorable than Templeton Emerging Markets Investment Trust.
Templeton Emerging Markets Investment Trust has lower revenue, but higher earnings than Dr. Martens. Dr. Martens is trading at a lower price-to-earnings ratio than Templeton Emerging Markets Investment Trust, indicating that it is currently the more affordable of the two stocks.
69.5% of Dr. Martens shares are held by institutional investors. Comparatively, 71.1% of Templeton Emerging Markets Investment Trust shares are held by institutional investors. 4.4% of Dr. Martens shares are held by company insiders. Comparatively, 0.6% of Templeton Emerging Markets Investment Trust shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 3.8%. Templeton Emerging Markets Investment Trust pays an annual dividend of GBX 6 per share and has a dividend yield of 3.1%. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Templeton Emerging Markets Investment Trust pays out 48.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Dr. Martens is clearly the better dividend stock, given its higher yield and lower payout ratio.
Templeton Emerging Markets Investment Trust has a net margin of 81.07% compared to Dr. Martens' net margin of 7.89%. Dr. Martens' return on equity of 18.91% beat Templeton Emerging Markets Investment Trust's return on equity.
Dr. Martens has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Templeton Emerging Markets Investment Trust has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.
In the previous week, Dr. Martens had 4 more articles in the media than Templeton Emerging Markets Investment Trust. MarketBeat recorded 6 mentions for Dr. Martens and 2 mentions for Templeton Emerging Markets Investment Trust. Templeton Emerging Markets Investment Trust's average media sentiment score of 1.26 beat Dr. Martens' score of 0.83 indicating that Templeton Emerging Markets Investment Trust is being referred to more favorably in the news media.
Summary
Dr. Martens beats Templeton Emerging Markets Investment Trust on 9 of the 17 factors compared between the two stocks.
Get Dr. Martens News Delivered to You Automatically
Sign up to receive the latest news and ratings for DOCS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Dr. Martens Competitors List
Related Companies and Tools
This page (LON:DOCS) was last updated on 7/20/2025 by MarketBeat.com Staff